Lincoln Pharmaceutical one of India's great company is expanding business with more export business. The company already has its presence in more than 60 countries, expects export business to cross Rs.225 crores in this financial year. In the next 2 to 3 years the company is targeting to increase the sales up to Rs.500 crores.

Managing Director of Lincoln Pharmaceuticals Limited, Mr Mahendra Patel said, "the export business has increased many folds to 54% of the sales in FY19 from 11% in FY11. For the FY18-19 company registered exports of Rs197.43cr. Export is the focus area for the company as margins are better and also the fact that off-late a lot of issues like price control, ban on FDC drugs (fixed dosage combination), sale of generic drugs, etc. have cropped up in the domestic market. Company has received many product registrations in countries like East and West Africa, South East Asia and Latin America and will look to expand presence in more countries."

Adding further he has said "Going forward, we are building a strong portfolio in lifestyle and chronic segment especially in women healthcare and dermatology to complement our strong presence in the acute segment. Company has recently secured a patent for its liquid Diclofenac Metered-Dose Rectal Spray (Diclofenac Rectal Spray). The company has necessary approvals from Drug Controller General of India (DCGI) and is set to launch it in Indian markets very soon. The Company is also planning to apply for a Global Patent for this novel solution. Over the next 2-3 years’ company is targeting sales of Rs500cr and vision to enter the league of ’Top 50 pharma cos' of India shortly," .